Table 1.
Baseline patient characteristics and tumor characteristics of high and low MPV/PC ratio groups with a cut-off value of 0.034.
| Total (%) | Low (%) | High (%) | p Value | |
|---|---|---|---|---|
| Age (years) | 0.377 | |||
| <65 | 32 (36.0) | 30 (69.8) | 27 (58.7) | |
| ≧65 | 57 (64.0) | 13 (30.2) | 19 (41.3) | |
| Gender | 0.821 | |||
| Female | 29 (32.6) | 15 (34.9) | 14 (30.4) | |
| Male | 61 (67.4) | 28 (65.1) | 33 (69.6) | |
| BMI (kg/m2) | 0.389 | |||
| <24 | 33 (37.1) | 18 (41.9) | 15 (32.6) | |
| ≧24 | 56 (62.9) | 25 (58.1) | 31 (67.4) | |
| Hypertension | 0.821 | |||
| No | 29 (32.6) | 15 (34.9) | 14 (30.9) | |
| Yes | 60 (67.4) | 28 (65.1) | 32 (69.6) | |
| Diabetes mellitus | 0.827 | |||
| No | 59 (66.3) | 28 (65.1) | 31 (67.4) | |
| Yes | 30 (33.7) | 15 (34.9) | 15 (32.6) | |
| CKD stage | 1.00 | |||
| 1 + 2 | 71 (79.8) | 34 (79.1) | 37 (80.4) | |
| 3 + 4 + 5 | 18 (20.2) | 9 (20.9) | 9 (19.6) | |
| Leukocytosis 1 | 0.083 | |||
| Yes | 9 (10.1) | 7 (16.3) | 2 (4.3) | |
| No | 80 (89.9) | 36 (83.7) | 44 (95.7) | |
| Neutrophilia 2 | 0.217 | |||
| Yes | 12 (15.8) | 8 (21.6) | 4 (10.3) | |
| No | 64 (84.2) | 29 (78.4) | 35 (89.7) | |
| NLR | 0.360 | |||
| ≧3 | 33 (42.3) | 18 (48.6) | 15 (36.6) | |
| <3 | 45 (57.7) | 19 (51.4) | 26 (63.4) | |
| Anemia 3 | 0.361 | |||
| No | 61 (68.5) | 27 (62.8) | 34 (73.9) | |
| Yes | 28 (31.5) | 16 (37.2) | 13 (26.1) | |
| ECOG PS | 0.109 | |||
| 0 | 86 (96.6) | 40 (93) | 46 (100) | |
| 1 | 3 (3.4) | 3 (7) | 0 (0) | |
| Nephrectomy | 0.289 | |||
| Radical | 48 (53.9) | 26 (60.5) | 22 (47.8) | |
| Partial | 41 (46.1) | 17 (39.5) | 24 (51.1) | |
| Smoking | 1.00 | |||
| No | 62 (69.7) | 30 (69.8) | 32 (69.6) | |
| Yes | 27 (30.3) | 13 (30.2) | 14 (30.4) | |
| T stage | 0.584 | |||
| T1 + T2 | 73 (82) | 34 (79.1) | 39 (84.8) | |
| T3 + T4 | 16 (18) | 9 (20.9) | 7 (15.2) | |
| LN involvement | 0.051 | |||
| No | 85 (95.5) | 39 (90.7) | 46 (100) | |
| Yes | 4 (4.5) | 4 (9.3) | 0 (0) | |
| Pathological stage | 0.600 | |||
| 1 + 2 | 71 (79.8) | 33 (76.7) | 38 (82.6) | |
| 3 + 4 | 18 (20.2) | 10 (23.3) | 8 (17.4) | |
| Histology | 0.818 | |||
| Clear cell | 62 (69.7) | 29 (67.4) | 33 (71.7) | |
| Other | 27 (30.3) | 14 (32.6) | 13 (28.3) | |
| Fuhrman grade 4 | 0.637 | |||
| 1 + 2 | 56 (68.3) | 26 (65.0) | 30 (71.4) | |
| 3 + 4 | 26 (31.7) | 14 (35.0) | 12 (28.6) | |
| Intratumor Hemorrhage |
0.389 | |||
| No | 33 (37.1) | 18 (41.9) | 15 (32.6) | |
| Yes | 56 (62.9) | 25 (58.1) | 31 (67.4) | |
| Intratumor Necrosis |
0.525 | |||
| No | 41 (46.1) | 18 (41.9) | 23 (50) | |
| Yes | 48 (53.9) | 25 (58.1) | 23 (50) |
BMI = body mass index, CKD = chronic kidney disease, NLR = Neutrophil-to-lymphocyte ratio, ECOG PS = Eastern Cooperative Oncology Group Performance Status; 1—leukocytosis was defined as white blood cell count > 100,000/Ul; 2—neutrophilia was defined as neutrophil count > 77,000/uL. Missing data were found in 13 patients; 3—anemia was defined as Hb < 12 g/dL; 4—Fuhrman grade was not applicable in 7 patients.